IPP Bureau
Brenntag partners with Qualifyze to enhance pharma audit offering
By IPP Bureau - August 09, 2023
Qualifyze specializes in Good Practice audits (GxP) audits and covers a wide range of areas, including excipients, starting materials, packaging, sustainability
Govt. passes National Dental Commission Bill, 2023
By IPP Bureau - August 09, 2023
The National Dental Commission Act 2023, will introduce a groundbreaking regulatory framework by establishing the National Dental Commission
Parliament passes National Nursing and Midwifery Commission (NNMC) Bill, 2023
By IPP Bureau - August 09, 2023
Several crucial provisions to elevate the standards of nursing education and services, enhance professional conduct, and ensure greater transparency and accountability introduced
KIMS posts Q1 FY24 consolidated PAT at Rs. 80.81 Cr
By IPP Bureau - August 08, 2023
KIMS has reported total income of Rs. 609.14 crores during the period ended June 30, 2023
Torrent Pharmaceuticals posts Q1 FY 24 consolidated PAT at Rs. 378 Cr
By IPP Bureau - August 08, 2023
Torrent Pharmaceuticals has reported total income of Rs. 2625 crores during the period ended June 30, 2023
Gland Pharma posts Q1 FY24 consolidated PAT at Rs. 194.10 Cr
By IPP Bureau - August 08, 2023
Gland Pharma has reported total income of Rs. 1246.23 crores during the period ended June 30, 2023
Surging demand for Korean pharma in 2023 ahead of CPHI Korea
By IPP Bureau - August 08, 2023
Pharma in Korea receives a 7% increase in ‘growth potential’ category according to the CPHI Annual Survey findings
Briefs: Dr. Reddy's Laboratories and Aurobindo Pharma
By IPP Bureau - August 06, 2023
The inspection closed with zero observations and a classification of No Action Indicated
Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr
By IPP Bureau - August 06, 2023
The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023
Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP
By IPP Bureau - August 06, 2023
The product is being launched in August 2023
Fortis Healthcare Q1 FY24 consolidated PAT drops at Rs. 111.76 Cr
By IPP Bureau - August 06, 2023
Fortis Healthcare has reported total income of Rs. 1665.55 crores during the period ended June 30, 2023
Indraprastha Medical Corporation Q1 FY24 PAT up at Rs. 30.50 Cr
By IPP Bureau - August 06, 2023
The company has reported total income of Rs. 310.07 crores during the period ended June 30, 2023
USFDA approves Merck’s ERVEBO for use in children 12 months of age and older
By IPP Bureau - August 05, 2023
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations
By IPP Bureau - August 05, 2023
The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023
